Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 89

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 89
---
) recommends
Ceftriaxone as the first-line treatment [2]. Resistance is a growing threat. However, strains resistant to Ceftriaxone are emerging,
posing a serious public health threat [3].

Liposomal Mupirocin IV is being developed
as a systemic treatment alternative in Ceftriaxone-resistant infections, with the potential to offer improved tissue penetration and
sustained drug exposure.

<div align='center'>54</div>

Pricing Benchmark and Market Assumptions

To estimate pricing, comparisons were made between small molecule
drugs and their nanoparticle/liposomal equivalents. For example:

| - | Conventional Amphotericin B: ~$51 per 
 50 mg dose                            |

| - | Liposomal                                                                             
 Amphotericin B (AmBisome®): ~$341 per dose which reflects a ~7x premium for liposomal 
 formulations [4].                                                                     |

Market pricing assumptions for Nano-Mupirocin:

| - | Ceftriaxone               
 (per treatment): $538 [5] |

| - | Topical                       
 Mupirocin (per 50g): ~$45 [6] |

| - | Estimated                                                                                
 price for Liposomal Nano-Mupirocin intramuscular (IM) and intravenous (IV) (assumption): 
 $315–$1,200 per course respectively                                                      |

| - | Average                                 
 estimated price used for modeling: $600 |

Epidemiology and Market Size for Resistant Gonorrhea

According to the CDC’s 2022 STD Surveillance
Report, the U.S. reports approximately 710,000 gonorrhea cases annually, with Ceftriaxone resistance emerging in approximately 5% of
cases [7], resulting in ~91,000 Ceftriaxone-resistant infections per year.

Estimations for U.S. annual revenue potential:

approximately 91,000 cases
× $600 = ~$55 million

Global Total Addressable Market (TAM):

Based on higher resistance
prevalence in parts of Asia and Europe, the global market is assumed at roughly four times the size of the U.S. market at around $220
million

Estimated revenue potential
at 30% market share: ~$70+ million/year globally

Clinical Background and Unmet Need

MRSA is a leading cause of hospital- and community-acquired
infections. The CDC estimates over 1.2